Early Relapse Within 6 Months of Idecabtagene Vicleucel Predicts Poor Survival in Relapsed Refractory Multiple Myeloma (IMS 2026) - Sep 11, 2026 - Abstract #PA-161; Pres time: Sep 25, 2026; "In this large real-world cohort of patients treated with SOC ide-cel, relapse within ≤6 months was associated with particularly poor outcomes, with a median OS of less than a year. Notably, nearly half of patients with early relapses lacked conventional high-risk features, underscoring the limitations of current baseline risk stratification approaches."
Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia
|
|
Sreeraj Vasudevan1; Donna Liza Thampan1; Mahmoud M. Gaballa2; Oren Pasvolsky2; Sarvari Yellapragada2; Carolina Schinke3; Krina Patel4; Muzaffar Qazilbash2; Meera Mohan2
|